Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 346 AL 360

In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease

Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):343-51. doi: 10.1007/s00259-010-1612-0. Epub 2010 Sep 16.

Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease

Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD.

J Pharmacol Exp Ther. 2011 Jan;336(1):38-46. doi: 10.1124/jpet.110.166876. Epub 2010 Sep 23.

Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease

Small G, Bullock R.

Alzheimers Dement. 2011 Mar;7(2):177-84. doi: 10.1016/j.jalz.2010.03.016. Epub 2010 Nov 5.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease

Collins LE, Paul NE, Abbas SF, Leser CE, Podurgiel SJ, Galtieri DJ, Chrobak JJ, Baqi Y, Müller CE, Salamone JD.

Pharmacol Biochem Behav. 2011 Sep;99(3):414-22. doi: 10.1016/j.pbb.2011.05.026. Epub 2011 May 27.

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group.

Arch Gen Psychiatry. 2011 Aug;68(8):853-61. doi: 10.1001/archgenpsychiatry.2011.72.

Presenile dementia: a case of Hashimoto's encephalopathy

Chong CS, Leung JL, Wong IH, Ng PW, Miao MY.

East Asian Arch Psychiatry. 2011 Mar;21(1):32-6.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Ehrnhoefer DE, Wong BK, Hayden MR.

Nat Rev Drug Discov. 2011 Oct 21;10(11):853-67. doi: 10.1038/nrd3556.

Epigenetic treatment of neurological disease

Gray SG.

Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders - contemporary approaches

Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):175-83. doi: 10.2174/187152711794480410.

Mitophagy in neurodegeneration: an opportunity for therapy?

Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.

Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim

Weinreb O, Mandel S, Bar-Am O, Amit T.

J Neural Transm (Vienna). 2011 Mar;118(3):479-92. doi: 10.1007/s00702-011-0597-6. Epub 2011 Mar 1.

Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases

Kawamata J, Shimohama S.

J Alzheimers Dis. 2011;24 Suppl 2:95-109. doi: 10.3233/JAD-2011-110173.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias